查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840760

前列腺癌診斷市場按產品類型、檢測類型、最終用戶、技術和應用分類－2025-2032年全球預測

Prostate Cancer Diagnostics Market by Product Type, Test Type, End User, Technology, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，攝護腺癌診斷市場規模將成長 43.3 億美元，複合年成長率為 14.60%。

關鍵市場統計數據
基準年 2024 14.5億美元
預計年份：2025年 16.7億美元
預測年份 2032 43.3億美元
複合年成長率 (%) 14.60%

前列腺癌的診斷處於快速發展的生物醫學科學與不斷變化的臨床實踐模式的關鍵交匯點。近年來，診斷路徑已從依賴單一檢測法篩檢工具發展為結合生物標記、分子平台、影像引導切片檢查和先進成像系統的整合策略。因此，臨床、商業和監管領域的相關人員正在重新評估如何更早地識別疾病、更準確地進行風險分層、減少不必要的侵入性操作，同時維持或改善治療效果。

在此背景下，診斷創新正受到多種技術趨勢的驅動。生物標記和套件的開發已從基礎蛋白質檢測發展到涵蓋基因和分子檢測套組，並通常結合先進的分析技術。 CT、MRI、PET 和超音波等影像系統正針對攝護腺應用進行最佳化，而切片檢查技術的改善也持續影響組織採集策略。這些發展共同重塑了臨床路徑，並促成了更個人化的診斷和治療方案。

隨著傳統模式的轉變，實驗室、醫院、門診手術中心和研究實驗室都在調整工作流程和資本規劃，以適應診斷技術的進步。臨床團隊積極採用新的檢測方法和模式，而支付方和政策制定者則在重新評估醫保覆蓋框架和實踐指南。本執行摘要深入分析了變革性轉變、結構性阻力（例如關稅的影響）、市場區隔資訊、區域動態、競爭對手的行動，並提出了切實可行的建議，以幫助領導者應對這一不斷變化的環境。

新的多模態診斷策略、分散式檢測以及不斷變化的報銷預期，正在從根本上改變前列腺癌的診療方式。

前列腺癌診斷領域正經歷重大變革，這既得益於科學突破，也源自於商業需求。包括次世代定序和基於PCR的檢測在內的分子診斷方法，已從小眾研究工具轉變為臨床上用於風險分層和指南切片檢查決策的重要工具。同時，先進的影像技術正與介入治療流程更加緊密地結合，從而實現標靶切片檢查並降低診斷的不確定性。

另一項重大轉變是向多模態診斷演算法的轉變，該演算法結合了生物標記、影像學和臨床參數，以最佳化切片檢查和治療的患者選擇。這種綜合方法減少了過度診斷，並支持更精準的治療路徑。此外，隨著門診手術和診斷中心採用即時檢測和更貼近患者的檢測方式，診斷的去中心化程度正在提高，這改變了醫院的轉診流程和資本投資決策。

為了適應新的診斷模式，監管和報銷環境也在不斷演變。支付方越來越關注基於價值的指標和真實世界證據，因此，臨床效用（而不僅僅是分析性能）的證明變得尤為重要。因此，企業和臨床團隊必須將證據的生成與以結果為導向的終點指標結合。總而言之，這些轉變正在加速從「一刀切」的篩檢轉向更符合患者風險狀況和治療目標的個人化診斷策略。

了解累積關稅變更對醫療診斷採購和部署的營運、採購和供應鏈的連鎖影響

政策變化和貿易行動可能對醫療設備和診斷供應鏈造成巨大的營運壓力，而2025年關稅調整的集中實施將產生一系列累積效應，需要密切關注。影響醫療設備、試劑和耗材的關稅上調往往會增加診斷影像系統、切片檢查設備和套件的到岸成本，進而影響醫院、診斷中心和門診手術中心的採購週期。當資本預算緊張時，決策者會優先考慮已證實有效的臨床效用和成本效益，即使臨床效益顯而易見，也可能導致新設備的引進被推遲。

除了直接的成本影響外，關稅還可能加速區域籌資策略和供應商多元化。製造商和買家可能會透過縮減某些生產活動、在不同地區尋找新的供應商或尋求最佳化關稅分類來減輕關稅的影響。此類應對措施通常需要一定的前置作業時間和投資，並可能暫時導致專用耗材或複雜影像處理組件的供應出現瓶頸。同時，供應商可能會調整定價模式、重新談判銷售合約或推出配套服務以維持市場進入。

重要的是，採購的不確定性會影響設備升級和培訓計畫的安排，從而對臨床營運產生間接影響。因此，醫療系統可能會推遲一些不太緊急的技術升級，延長現有設備的使用壽命，或採取選擇性部署策略，將新功能集中在卓越中心。對於診斷生態系統中的相關人員，積極監測供應鏈和政策，並制定緊急計畫，對於應對關稅波動帶來的持續連鎖反應至關重要。

透過整合產品、測試類型、最終用戶、技術和應用維度進行細分分析，以發現策略重點和臨床工作流程機會。

對細分市場的細緻分析揭示了臨床需求、技術能力和最終用戶背景如何交匯融合，從而創造差異化的商業機會。產品類型包括生物標記及套件、切片針及影像系統；生物標記及套件又細分為基因檢測套組、分子診斷試劑套件及PSA檢測；影像系統則細分為CT系統、MRI系統、PET系統及超音波系統。這種層級式的產品分類與檢測類型細分相交，包括切片檢查、影像檢查、分子檢測和PSA檢測；影像檢查又細分為CT、MRI、PET和超音波；分子檢測則細分為NGS和PCR檢測。從產品和檢測類型兩個角度來看，臨床工作流程中最容易受到干擾的環節以及診斷和介入治療流程整合能夠帶來最大臨床效益的環節都至關重要。

檢驗最終用戶細分，可以明確技術採納路徑。門診手術中心、診斷中心、醫院和研究診所以及實驗室的資本狀況、吞吐量預期和臨床範圍各不相同，這些因素會影響技術選擇和服務模式。以技術為中心的細分透過區分影像模式、免疫檢測和分子診斷，進一步縮小了機會領域。影像模式包括CT、MRI、PET和超音波模式；免疫檢測包括ELISA和RIA平台；分子診斷包括NGS和PCR技術。最後，應用細分——基因檢測、早期診斷以及監測和追蹤——針對不同的臨床決策點和證據要求，其中監測應用通常需要縱向資料整合和標準化報告。

透過整合這些細分視角，相關人員可以更好地制定產品開發和商業化策略，這些策略考慮特定模式的工作流程整合、最終用戶的採購行為以及初始診斷與縱向監測背景下不同的證據標準。

區域動態和基礎設施差異將影響美洲、歐洲、中東和非洲以及亞太地區的前列腺癌診斷普及趨勢。

區域動態持續影響著前列腺癌診斷技術的普及性和商業化策略。在美洲，醫療系統和私人機構正透過投資分子平台和先進影像系統來回應精準診斷的臨床需求。相較之下，由於監管協調、國家篩檢政策和醫療基礎設施的差異，歐洲、中東和非洲的普及速度各不相同。

亞太地區正經歷著都市區三級醫療機構快速採用新技術以及區域醫院和診斷中心持續提升診療能力的雙重挑戰。該地區的需求既受到公共衛生措施的推動，也受到私人對診斷創新投資的驅動。在所有地區，門診手術中心和診斷中心都是推廣新型檢測方法和分散醫療服務的關鍵管道。此外，一個地區的法律規範、報銷環境和醫療服務提供者的分佈情況，將決定新型生物標記檢測法、成像系統和分子檢測從臨床研究到常規應用的轉化速度。

因此，企業和醫療機構必須採取量身定做的策略，充分考慮基礎設施成熟度、支付方期望以及臨床指南的採納情況。區域臨床領導者、有針對性的證據產生以及靈活的部署模式對於將全球創新與本地實施實際情況相結合至關重要。

平台創新、策略夥伴關係和證據產生驅動的競爭格局將加速整合診斷解決方案和服務導向商業化進程。

前列腺癌診斷生態系統中的競爭者們持續投資於平台升級、策略夥伴關係以及與學術機構和臨床中心進行實證合作。現有的醫療設備和診斷設備製造商不斷改進CT、MRI、PET和超音波等影像系統，以更好地支援前列腺癌特異性方案和融合引導切片檢查流程。同時，分子診斷專家們正在擴展檢測項目，並簡化次世代定序和基於PCR的檢測流程，以促進更快、更整合的臨床檢測。

隨著市場向涵蓋生物標記檢測、影像引導採樣和下游分子分析的捆綁式診斷解決方案轉型，套件製造商與影像及介入設備製造商之間的合作日益普遍。此外，將資本投資與培訓、工作流程最佳化和售後資訊服務結合的服務模式，也越來越受到希望降低新技術應用複雜性的終端用戶的青睞。研究機構和學術中心仍然是新型生物標記檢驗和臨床效用研究的重要合作夥伴，協助商業公司建構更強力的真實世界證據。

鑑於這些動態，成功的公司會優先考慮跨部門協作、協調一致的監管策略以及健全的上市後監測，以證明其臨床價值。它們還會投資於可擴展的生產製造和多元化的供應鏈，以保持對市場的應對力，並降低政策和關稅相關干擾的影響。

為技術開發商、醫療系統和投資者提供實際的策略行動，以加速技術應用、保障供應鏈並展現持久的臨床價值。

行業領導者可以採取多項切實可行的措施來確保臨床相關性和商業性韌性。首先，透過投資於能夠顯著降低診斷不確定性和後續流程負擔的檢測方法和檢測手段，使產品開發與臨床路徑保持一致。其次，優先與臨床中心和診斷網路建立夥伴關係，共同設計工作流程，簡化實施過程，並顯著改善切片檢查和治療決策的患者選擇。透過這些措施，供應商可以縮短引進週期，並獲得臨床醫生的認可。

第三，透過製造多元化、關鍵耗材二級供應商認證以及積極監測關稅和貿易政策，增強供應鏈韌性。第四，採用靈活的商業模式，將資本設備與結果掛鉤的服務、培訓和數據分析相結合，以降低預算受限的終端用戶的採用門檻。第五，投資生成符合支付方價值框架的真實世界證據。真實世界臨床試驗和基於註冊登記的證據對於證明不同醫療環境中的臨床效用尤為重要。

最後，要使本地市場策略與當地的監管和報銷實際情況相符，同時利用卓越中心來展現臨床和營運價值。領導者落實這些優先事項，將提高新診斷技術從創新到常規臨床實踐順利過渡的可能性。

一項綜合性的多方法研究途徑，結合了臨床訪談、文獻綜述、方案案例研究和供應鏈情境分析，提供了嚴謹的見解。

本報告整合了多種方法論的證據，以確保得出可靠且可重複的結論。主要研究包括對來自醫院、門診手術中心、診斷中心和實驗室的臨床專家、實驗室主任和採購負責人進行結構化訪談，以了解他們對工作流程整合、採購標準和臨床效用的在地化觀點。次要分析包括對同行評審文獻、臨床指南、監管文件、成像和檢測平台的技術規範以及製造商文件進行嚴格的審查，以明確技術能力和檢驗途徑。

此外，我們也進行了案例研究和方案審查，以評估分子診斷、影像系統、生物標記和切片檢查技術在實際應用中的情況。我們透過情境分析和專家諮詢評估了供應鏈和政策影響，以確定應對關稅變化和零件供應限制的可行營運方案。作為品質保證措施，我們將檢驗結果與已發表的臨床結果進行交叉檢驗，並對來自多個來源的數據進行三角測量，以減少偏差並確保結果的一致性。

調查方法強調透明度和可重複性，包括記錄訪談通訊協定、標註文獻來源以及明確納入二手文獻的標準。這種多方法策略能夠全面評估技術可行性以及影響不同醫療機構實施的實際障礙。

整合臨床、營運和政策因素，以確定診斷創新是否能改善患者預後並實現永續的醫療保健價值。

前列腺癌的診斷正朝著更整合、個人化和實證的治療模式發展。分子檢測、精細化的生物標記檢測法和影像系統的融合，使臨床醫生能夠更明智地決定何時進行切片檢查、如何進行靶向取樣以及如何長期監測患者。同時，諸如關稅驅動的供應鏈調整和不斷變化的報銷預期等營運壓力，凸顯了製造商和醫療保健系統戰略靈活性的必要性。

展望未來，最具影響力的成功因素將是已證實的臨床效用、便於工作流程的解決方案以及能夠應對當地基礎設施和政策實際情況的穩健商業化策略。技術提供者、臨床機構和支付方之間的合作對於協調指導證據產生和應用的決策標準至關重要。透過專注於整合的診斷路徑和可操作的證據，相關人員可以減少不必要的手術，最佳化資源利用，並最終改善以病人為中心的治療效果。

總而言之，如果將技術創新與清晰的臨床效用描述以及降低供應和政策相關風險的營運計劃相結合，診斷生態系統將能夠為前列腺癌治療帶來有意義的改進。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合人工智慧和機器學習技術，提高攝護腺癌診斷準確率，減少假陽性結果
  • 利用液態生物檢體平台對前列腺癌循環腫瘤DNA生物標記進行非侵入性檢測
  • 多參數磁振造影結合超音波融合技術的廣泛應用提高了前列腺病變的早期診斷率。
  • 開發和臨床檢驗一種用於前列腺癌篩檢的尿液外泌體和微型RNA檢測方法
  • 將PSMA PET影像引入常規診斷流程，以提高轉移性前列腺癌的檢出率
  • 前列腺診斷中次世代定序技術的監管核准途徑和報銷策略
  • 遠端醫療的引入使得遠距前列腺癌篩檢和即時解讀診斷結果成為可能。
  • 開發照護現場診斷設備
  • 診斷設備製造商與大學癌症中心合作，發現了前列腺癌的新型表觀遺傳生物標記。
  • 將深度學習演算法與數位病理學結合，實現前列腺切片檢查分級和預後評估的自動化

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 攝護腺癌診斷市場（依產品類型分類）

  • 生物標記和套件
    • 基因檢測套組
    • 分子診斷試劑套件
    • PSA檢測
  • 切片穿刺針
  • 影像系統
    • CT系統
    • 磁振造影系統
    • PET系統
    • 超音波系統

第9章 前列腺癌診斷市場（依檢測類型分類）

  • 切片檢查
  • 影像檢查
    • CT掃描
    • 磁振造影
    • PET掃描
    • 超音波
  • 分子檢測
    • NGS檢測
    • PCR檢測
  • PSA檢測

第10章 攝護腺癌診斷市場（依最終用戶分類）

  • 門診手術中心
  • 診斷中心
  • 醫院和診所
  • 實驗室

第11章 攝護腺癌診斷市場（依技術分類）

  • 診斷影像設備
    • CT模式
    • 磁振造影技術
    • PET影像方式
    • 超音波
  • 免疫檢測
    • ELISA
    • RIA
  • 分子診斷
    • NGS技術
    • PCR技術

第12章 攝護腺癌診斷市場（依應用分類）

  • 基因檢測
  • 初步診斷
  • 監測和後續行動

第13章 攝護腺癌診斷市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 前列腺癌診斷市場（依群體分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國前列腺癌診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Roche Diagnostics International AG
    • Abbott Laboratories
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • Hologic, Inc.
    • bioMerieux SA
    • QIAGEN NV
    • Laboratory Corporation of America Holdings
    • Illumina, Inc.
Product Code: MRR-A339DAEFAC09

The Prostate Cancer Diagnostics Market is projected to grow by USD 4.33 billion at a CAGR of 14.60% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.45 billion
Estimated Year [2025] USD 1.67 billion
Forecast Year [2032] USD 4.33 billion
CAGR (%) 14.60%

Prostate cancer diagnostics sits at a pivotal intersection between rapidly advancing biomedical science and shifting clinical practice patterns. Recent years have seen diagnostic pathways evolve from a heavy reliance on single-measure screening tools to integrated strategies that combine biomarkers, molecular platforms, image-guided biopsy, and advanced imaging systems. As a result, stakeholders across clinical, commercial, and regulatory domains are reevaluating how to identify disease earlier, stratify risk more precisely, and reduce unnecessary invasive procedures while preserving or improving outcomes.

In this context, diagnostics innovation is driven by multiple technological streams. Biomarker and kit development has matured beyond basic protein assays to include genetic and molecular testing kits, which are frequently paired with sophisticated analytics. Imaging systems such as CT, MRI, PET, and ultrasound are increasingly optimized for prostate applications, and biopsy technology and technique refinement continue to shape tissue acquisition strategy. Together, these developments are reshaping clinical pathways and enabling more personalized approaches to diagnosis and management.

Transitioning from traditional paradigms, laboratories, hospitals, ambulatory surgical centers, and research laboratories are adapting workflows and capital plans to accommodate these diagnostic advances. As clinical teams integrate new tests and modalities, payers and policymakers are simultaneously reassessing coverage frameworks and care guidelines. The remainder of this executive summary synthesizes transformative shifts, structural headwinds such as tariff implications, segmentation intelligence, regional dynamics, competitor actions, and actionable recommendations for leaders navigating this evolving landscape.

How emerging multimodal diagnostic strategies, decentralized testing, and evolving reimbursement expectations are fundamentally altering prostate cancer care delivery

The diagnostic landscape for prostate cancer is experiencing transformative shifts driven by both scientific breakthroughs and operational imperatives. Molecular diagnostics, including next-generation sequencing and PCR-based assays, have transitioned from niche research tools to clinically relevant instruments that inform risk stratification and guide biopsy decisions. At the same time, advanced imaging modalities have become more tightly integrated with interventional workflows, enabling targeted biopsies and reducing diagnostic uncertainty.

Another major shift is the movement toward multimodal diagnostic algorithms that combine biomarkers, imaging, and clinical parameters to refine patient selection for biopsy and therapy. This integrative approach reduces overdiagnosis and supports more precise treatment pathways. Furthermore, decentralization of diagnostics is advancing as ambulatory surgical centers and diagnostic centers adopt point-of-care and near-patient testing options, altering referral flows and capital investment decisions made by hospitals.

Regulatory and reimbursement landscapes are also evolving to accommodate new diagnostic paradigms. Payers are increasingly focused on value-based metrics and real-world evidence, which elevates the importance of demonstrating clinical utility beyond analytical performance. Consequently, companies and clinical teams must align evidence generation with outcome-focused endpoints. Taken together, these shifts are accelerating a move from one-size-fits-all screening toward personalized diagnostic strategies that better match patient risk profiles and care goals.

Understanding the cascading operational, procurement, and supply chain consequences of cumulative tariff changes on medical diagnostics procurement and deployment

Policy changes and trade actions can exert meaningful operational pressure on medical device and diagnostic supply chains, and the aggregation of tariff adjustments in 2025 has created a set of cumulative impacts that warrant close attention. Tariff increases affecting medical equipment, reagents, and consumables tend to raise landed costs for imaging systems, biopsy devices, and kits, which in turn influences procurement cycles for hospitals, diagnostic centers, and ambulatory surgical centers. When capital budgets are constrained, decision-makers prioritize proven clinical utility and cost-effectiveness, which can slow adoption of newer devices even when they offer clear clinical benefits.

Beyond immediate cost implications, tariffs can accelerate regional sourcing strategies and supplier diversification efforts. Manufacturers and purchasers may respond by reshoring certain production activities, qualifying additional suppliers in different geographies, or seeking tariff classification optimizations to mitigate duty exposure. These responses often require lead time and investment, and they can create temporary bottlenecks in availability of specialized consumables or complex imaging components. In parallel, suppliers may adjust pricing models, renegotiate distribution agreements, or introduce bundled service offerings to preserve market access.

Importantly, clinical operations feel secondary effects as procurement uncertainty influences scheduling for capital upgrades and training programs. As a result, health systems may defer nonurgent technology refreshes, extend the lifecycle of existing assets, or adopt selective deployment strategies that concentrate new capabilities in centers of excellence. For stakeholders in the diagnostic ecosystem, proactive supply chain and policy monitoring, coupled with contingency planning, are essential to navigate the persistent ripple effects of tariff shifts.

Integrated segmentation analysis that links product, test type, end-user, technology, and application dimensions to reveal strategic priorities and clinical workflow opportunities

A nuanced view of segmentation reveals where clinical need, technology capability, and end-user context converge to create differentiated opportunities. Product type segmentation spans Biomarkers & Kits, Biopsy Needles, and Imaging Systems, with Biomarkers & Kits further differentiated into Genetic Testing Kits, Molecular Diagnostic Kits, and PSA Tests, and Imaging Systems encompassing CT Systems, MRI Systems, PET Systems, and Ultrasound Systems. This layered product taxonomy intersects with test-type segmentation, which includes Biopsy, Imaging Tests, Molecular Tests, and PSA Test, while Imaging Tests are broken into CT Tests, MRI Tests, PET Tests, and Ultrasound Tests and Molecular Tests are delineated between NGS Tests and PCR Tests. Together, product and test-type perspectives illuminate where clinical workflows are most disrupted and where integration between diagnostics and interventional procedures yields the greatest clinical return.

Examining end-user segmentation clarifies adoption pathways: Ambulatory Surgical Centers, Diagnostic Centers, Hospitals & Clinics, and Research Laboratories each have distinct capital profiles, throughput expectations, and clinical scope, which shape technology selection and service models. Technology-focused segmentation further refines opportunity areas by distinguishing Imaging Modalities, Immunoassays, and Molecular Diagnostics, with Imaging Modalities comprising CT, MRI, PET, and Ultrasound Modalities, Immunoassays including ELISA and RIA platforms, and Molecular Diagnostics covering NGS and PCR technologies. Finally, application segmentation-Genetic Testing, Initial Diagnosis, and Monitoring & Follow-Up-maps to different clinical decision points and evidence requirements, with monitoring applications often demanding longitudinal data integration and standardized reporting.

By synthesizing these segmentation lenses, stakeholders can better target product development and commercialization strategies that account for modality-specific workflow integration, end-user procurement behavior, and the differing evidence standards across initial diagnosis versus longitudinal monitoring contexts.

Regional dynamics and infrastructure variations that determine adoption trajectories for prostate cancer diagnostics across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to shape adoption curves and commercialization strategies in prostate cancer diagnostics. In the Americas, health systems and private providers are responding to clinical demand for precision diagnostics by investing in molecular platforms and advanced imaging systems, while also emphasizing value-based procurement and outcome-driven evidence generation. In contrast, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization, national screening policies, and variable healthcare infrastructure produce diverse adoption rhythms; certain Western European markets are early adopters of integrated diagnostic pathways, whereas other markets are focused on improving access to basic imaging and laboratory services.

Asia-Pacific reflects a mix of rapid technology adoption in urban tertiary centers and continued capacity-building in regional hospitals and diagnostic centers. Demand in that region is driven by both public health initiatives and private-sector investments in diagnostic innovation. Across all regions, ambulatory surgical centers and diagnostic centers are important vectors for dissemination of new testing modalities and for decentralizing care. Moreover, the interplay between local regulatory frameworks, reimbursement environments, and supplier footprint determines how quickly new biomarker assays, imaging systems, and molecular tests transition from clinical research to routine practice.

Consequently, companies and healthcare organizations must adopt regionally tailored strategies that account for infrastructure maturity, payer expectations, and clinical guideline adoption. Local clinical champions, targeted evidence generation, and adaptive deployment models are essential to bridge global innovation with regional implementation realities.

Competitive dynamics driven by platform innovation, strategic partnerships, and evidence generation that accelerate integrated diagnostic solutions and service-oriented commercialization

Competitive activity within the prostate cancer diagnostics ecosystem is characterized by sustained investment in platform enhancements, strategic partnerships, and evidence-building collaborations with academic and clinical centers. Established medical device and diagnostic manufacturers continue to refine imaging systems across CT, MRI, PET, and ultrasound modalities to better support prostate-specific protocols and fusion-guided biopsy workflows. At the same time, specialist firms in molecular diagnostics are expanding assay menus and streamlining workflows for next-generation sequencing and PCR-based tests to facilitate clinical integration and faster turnaround times.

Partnerships between kit manufacturers and imaging or interventional device companies are becoming more common as the market moves toward bundled diagnostic solutions that span biomarker testing, image-guided sampling, and downstream molecular analysis. Additionally, service models that pair capital equipment with training, workflow optimization, and post-sale data services are gaining traction among end-users seeking to reduce the complexity of deploying new technologies. Research laboratories and academic centers remain key collaborators for novel biomarker validation and clinical utility studies, enabling commercial players to build stronger real-world evidence packages.

Given these dynamics, successful companies prioritize cross-functional collaboration, regulatory strategy alignment, and robust post-market surveillance to demonstrate clinical value. They also invest in scalable manufacturing and diversified supply chains to mitigate policy and tariff-related disruptions while preserving market responsiveness.

Practical strategic actions for technology developers, health systems, and investors to accelerate adoption, secure supply chains, and demonstrate enduring clinical value

Industry leaders can take several actionable steps to secure clinical relevance and commercial resilience. First, align product development with clinical pathways by investing in modalities and assays that demonstrably reduce diagnostic uncertainty and downstream procedural burden. Second, prioritize partnerships with clinical centers and diagnostic networks to co-design workflows that simplify implementation and deliver measurable improvements in patient selection for biopsy and treatment decisions. By doing so, vendors can shorten adoption cycles and foster clinician buy-in.

Third, strengthen supply chain resilience through diversification of manufacturing, qualification of secondary suppliers for critical consumables, and proactive tariff and trade policy monitoring. Fourth, adopt flexible commercial models that combine capital equipment with outcome-linked services, training, and data analytics to lower adoption hurdles for end-users with constrained budgets. Fifth, invest in real-world evidence generation that aligns with payer value frameworks; pragmatic studies and registry-based evidence are particularly valuable in demonstrating clinical utility across diverse care settings.

Finally, tailor regional go-to-market strategies to local regulatory and reimbursement realities while leveraging centers of excellence to demonstrate clinical and operational value. When leaders execute these priorities, they improve the probability that new diagnostic technologies will transition smoothly from innovation to routine clinical practice.

Comprehensive multi-method research approach combining primary clinical interviews, literature synthesis, protocol case studies, and supply chain scenario analysis to ensure rigorous insights

This report synthesizes evidence from multiple methodological pillars to ensure robust, reproducible insights. Primary research activities involved structured interviews with clinical specialists, laboratory directors, and procurement leaders across hospitals, ambulatory surgical centers, diagnostic centers, and research laboratories to capture frontline perspectives on workflow integration, purchasing criteria, and clinical utility. Secondary analysis encompassed a rigorous review of peer-reviewed literature, clinical guidelines, regulatory filings, technical specifications for imaging and assay platforms, and manufacturer documentation to contextualize technological capabilities and validation pathways.

In addition, case studies and protocol reviews were used to assess how molecular diagnostics, imaging systems, biomarkers, and biopsy techniques are being operationalized in real-world settings. Supply chain and policy impacts were evaluated through scenario analysis and expert consultation to identify plausible operational responses to tariff shifts and component availability constraints. Quality assurance procedures included cross-validation of interview findings with published clinical outcomes and triangulation across multiple data sources to limit bias and ensure consistency.

The methodological approach emphasizes transparency and replicability, with documented interview protocols, source annotations, and a clear statement of inclusion criteria for secondary literature. This multi-method strategy affords a balanced view of both technological potential and the pragmatic barriers that influence adoption across varied healthcare environments.

Synthesis of clinical, operational, and policy factors that will determine whether diagnostic innovations translate into improved patient outcomes and sustainable healthcare value

Prostate cancer diagnostics is transitioning toward a more integrated, personalized, and evidence-driven model of care. The convergence of molecular testing, refined biomarker assays, and enhanced imaging systems is enabling clinicians to make more informed decisions about when to biopsy, how to target sampling, and how to monitor patients over time. Meanwhile, operational pressures such as tariff-induced supply chain adjustments and changing reimbursement expectations underscore the need for strategic agility among manufacturers and health systems.

Looking ahead, the most influential success factors will be demonstrable clinical utility, workflow-friendly solutions, and resilient commercialization strategies that respond to local infrastructure and policy realities. Collaboration between technology providers, clinical sites, and payers will be central to aligning evidence generation with the decision-making criteria that govern adoption. By focusing on integrated diagnostic pathways and pragmatic evidence, stakeholders can reduce unnecessary procedures, optimize resource use, and ultimately improve patient-centered outcomes.

In sum, the diagnostic ecosystem is positioned to deliver meaningful improvements in prostate cancer care, provided that innovation is paired with a clear articulation of clinical benefit and an operational plan that mitigates supply and policy-related risks.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence and machine learning to improve prostate cancer diagnostic accuracy and reduce false positives
  • 5.2. Adoption of liquid biopsy platforms for noninvasive detection of prostate cancer circulating tumor DNA biomarkers
  • 5.3. Expansion of multiparametric MRI use combined with ultrasound fusion to enhance early prostate lesion characterization
  • 5.4. Development and clinical validation of urinary exosome and microRNA assays for prostate cancer screening
  • 5.5. Emergence of PSMA PET imaging in routine diagnostic workflows to improve metastatic prostate cancer detection
  • 5.6. Regulatory approval pathways and reimbursement strategies for next generation sequencing panels in prostate diagnostics
  • 5.7. Implementation of telemedicine enabled remote prostate cancer screening and real time diagnostic result interpretation
  • 5.8. Growth of point of care diagnostic devices for rapid assessment of prostate specific antigen kinetics in outpatient settings
  • 5.9. Collaboration between diagnostic manufacturers and academic cancer centers for discovery of novel epigenetic prostate cancer biomarkers
  • 5.10. Integration of deep learning algorithms with digital pathology to automate grading and prognostic assessment of prostate biopsy specimens

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Prostate Cancer Diagnostics Market, by Product Type

  • 8.1. Biomarkers & Kits
    • 8.1.1. Genetic Testing Kits
    • 8.1.2. Molecular Diagnostic Kits
    • 8.1.3. Psa Tests
  • 8.2. Biopsy Needles
  • 8.3. Imaging Systems
    • 8.3.1. Ct Systems
    • 8.3.2. Mri Systems
    • 8.3.3. Pet Systems
    • 8.3.4. Ultrasound Systems

9. Prostate Cancer Diagnostics Market, by Test Type

  • 9.1. Biopsy
  • 9.2. Imaging Tests
    • 9.2.1. Ct Tests
    • 9.2.2. Mri Tests
    • 9.2.3. Pet Tests
    • 9.2.4. Ultrasound Tests
  • 9.3. Molecular Tests
    • 9.3.1. Ngs Tests
    • 9.3.2. Pcr Tests
  • 9.4. Psa Test

10. Prostate Cancer Diagnostics Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Diagnostic Centers
  • 10.3. Hospitals & Clinics
  • 10.4. Research Laboratories

11. Prostate Cancer Diagnostics Market, by Technology

  • 11.1. Imaging Modalities
    • 11.1.1. Ct Modalities
    • 11.1.2. Mri Modalities
    • 11.1.3. Pet Modalities
    • 11.1.4. Ultrasound Modalities
  • 11.2. Immunoassays
    • 11.2.1. Elisa
    • 11.2.2. Ria
  • 11.3. Molecular Diagnostics
    • 11.3.1. Ngs Technologies
    • 11.3.2. Pcr Technologies

12. Prostate Cancer Diagnostics Market, by Application

  • 12.1. Genetic Testing
  • 12.2. Initial Diagnosis
  • 12.3. Monitoring & Follow-Up

13. Prostate Cancer Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Prostate Cancer Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Prostate Cancer Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Roche Diagnostics International AG
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Danaher Corporation
    • 16.3.4. Thermo Fisher Scientific Inc.
    • 16.3.5. Siemens Healthineers AG
    • 16.3.6. Hologic, Inc.
    • 16.3.7. bioMerieux SA
    • 16.3.8. QIAGEN N.V.
    • 16.3.9. Laboratory Corporation of America Holdings
    • 16.3.10. Illumina, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. PROSTATE CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. PROSTATE CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PROSTATE CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA PROSTATE CANCER DIAGN